MoonLake Immunotherapeutics
MLTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001821586
In the last 90 days, MoonLake Immunotherapeutics insiders filed 0 open-market purchases and 5 sales; 172 institutions reported holding it in 13F filings for Q2 2026, worth $1.43B in total; no superinvestor holds it.
Q1 2022 vs. Q4 2021
How the institutions holding MoonLake Immunotherapeutics changed between Q4 2021 and Q1 2022.
All holders in Q1 2022All holders in Q4 2021
| Measure | Q4 2021 | Q1 2022 | Change |
|---|---|---|---|
| Holders | 45 | 27 | −18 |
| Shares | 11.4M | 11.6M | +141.4K (+1.2%) |
| Value | $112.8M | $123.4M | +$10.6M (+9.4%) |
New holders (7)
Institutions that held MoonLake Immunotherapeutics at the end of Q1 2022 but not at the end of Q4 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Beryl Capital Management LLC | 459,243 | $5.10M | 0.31% |
| Jane Street Group, LLC | 65,437 | $726.0K | 0.00% |
| Fir Tree Capital Management LP | 61,866 | $619.0K | 0.02% |
| Omers Administration Corp | 46,247 | $513.0K | 0.01% |
| Ergoteles LLC | 14,613 | $162.0K | 0.01% |
| UBS Group AG | 1,692 | $19.0K | 0.00% |
| Clear Street LLC | 801 | $9.00K | 0.00% |
Sold out (25)
Institutions that held MoonLake Immunotherapeutics at the end of Q4 2021 and filed for Q1 2022 without it.